---
id: antimicrobials_ceftazidime-avibactam_030
category: antimicrobials
tags: [antimicrobials, ceftazidime-avibactam, CAZ-AVI, CRE, KPC, advanced-antibiotics]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Ceftazidime-Avibactam (CAZ-AVI)

**Q:** What is the spectrum of ceftazidime-avibactam, what does it NOT cover, and what are its FDA-approved indications?

**A:**

**Mechanism:**
- **Ceftazidime:** 3rd-gen cephalosporin (anti-Pseudomonal)
- **Avibactam:** Non-β-lactam β-lactamase inhibitor (diazabicyclooctane class)

**Spectrum - What it COVERS:**
- **CRE with KPC** (>99% susceptible, MIC50 0.06 mg/L)
- **OXA-48** carbapenemases
- **ESBL-producing** Enterobacterales
- **AmpC** β-lactamases
- **MDR Pseudomonas aeruginosa** (97.5% of carbapenem-resistant strains susceptible)

**Spectrum - What it DOES NOT cover:**
- ❌ **Metallo-β-lactamases (MBLs):** NDM, VIM, IMP
- ❌ **Anaerobes** (limited activity)
- ❌ **Atypicals**

**Key Point for MBLs:**
- **CAZ-AVI + Aztreonam** is first-line for MBL-producing CRE
- Aztreonam is stable to MBLs, avibactam protects aztreonam from serine β-lactamases

**FDA-Approved Indications:**
1. Complicated intra-abdominal infections (cIAI) - with metronidazole
2. Complicated urinary tract infections (cUTI), including pyelonephritis
3. Hospital-acquired pneumonia (HAP)/Ventilator-associated pneumonia (VAP)
4. Bacteremia (often off-label but guideline-recommended for CRE)

**Dosing:**
- 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV q8h
- Renal dose adjustment required

**Mnemonic: "CAZ-AVI Kills KPC, But NOT NDM"**
- **K**PC ✅
- **N**DM ❌ (MBL)
- Use **CAZ-AVI + Aztreonam** for NDM

**Clinical Pearl:**
- Resistance can develop during therapy (KPC variants)
- Consider combination therapy for high inoculum infections

**Media:** None

**Sources:** [CID 2016 - Second-generation BL/BLI], [PMC 2024 - Meta-analysis bacteremia/pneumonia], [PMC 2021 - CAZ-AVI review], [CDC EID 2024 - Rapid detection], [Scientific Reports 2025 - CAZ-AVI + aztreonam synergy]
